Sugi Predict

Sugi Predict / Compounds / SCHEMBL1474089

SCHEMBL1474089

SCHEMBL1474089

CC(C)(C)c1ccc(O)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.42
▸ TYR P14679 2/20 0.42
▸ DEGS1 O15121 1/20 0.42
▸ ESR1 P03372 8/20 0.37
▸ ESR2 Q92731 7/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ AR P10275 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ ESRRG P62508 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ NR1I2 O75469 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ MIF P14174 1/20 0.37
▸ ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484952 1.00 LMNA (0.42) LMNATYRDEGS1ESR1ESR2
SCHEMBL24922323 0.84 DEGS1 (0.38) LMNATYRDEGS1ESR1ESR2
SCHEMBL1511379 0.79 TRPV4 (0.36) LMNATYRDEGS1ESR1ESR2
SCHEMBL19413034 0.79 ESR1 (0.39) LMNATYRDEGS1ESR1ESR2
SCHEMBL227613 0.76 TRPV4 (0.58) DEGS1ESR1ESR2CYP2C9
SCHEMBL29918406 0.76 TRPV4 (0.58) DEGS1ESR1ESR2CYP2C9
SCHEMBL25318774 0.76 ENPP2 (0.45) LMNADEGS1ESR1ALDH1A1ENPP2
SCHEMBL146646 0.75 CCR1 (0.52) CYP3A4TSHRALDH1A1ACHEMEN1
SCHEMBL14327688 0.75 KIF11 (0.38) TSHRCYP2C19NPC1RAB9A
Methane SCHEMBL28516008 0.74 TRPV4 (0.56) DEGS1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140145105-A1 DYE-SENSITIZED SOLAR CELL FOR VEHICLE HYUNDAI MOTOR COMPANY (KR) 2014-05-29 — — US claimed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 — — EP disclosed
US-12479834-B2 Phenol compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-11-25 — — US disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 — — US disclosed
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-05-23 — — US disclosed
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 — — EP disclosed
CN-116854632-A Synthesis method and application of large-steric-hindrance heteroatom compound 深圳职业技术学院 2023-10-10 — — CN disclosed
US-11771684-B2 Inhibitors of dihydroceramide desaturase for treating disease CENTAURUS THERAPEUTICS (US) 2023-10-03 — — US disclosed
CN-114409685-B Organic micromolecule electroluminescent material, and preparation method and application thereof 华南理工大学 2023-07-21 — — CN disclosed
CN-115947681-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-04-11 — — CN disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 — — US disclosed
EP-2291078-A1 OXAZOLOBENZIMIDAZOLE DERIVATIVES Merck Sharp & Dohme Corp. (US) 2011-03-09 — — EP disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 — — US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 — — US disclosed
WO-2009140163-A1 OXAZOLOBENZIMIDAZOLE DERIVATIVES MERCK & CO., INC. (US) 2009-11-19 — — WO disclosed
WO-2009140163-A1 OXAZOLOBENZIMIDAZOLE DERIVATIVES MERCK & CO., INC. (US) 2009-11-19 — — WO disclosed
US-7498341-B2 antidiabetic agents; type 2 diabetes SANOFI AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-03 — — US disclosed
US-7498341-B2 antidiabetic agents; type 2 diabetes SANOFI AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-03 — — US disclosed
WO-2006097817-A9 N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER JAPAN INC (JP) 2006-12-07 — — WO disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11771684-B2 Inhibitors of dihydroceramide desaturase for treating disease CERS2, DEGS1, SMPD1 LMNA 1954/4885TYR 4737/4885DEGS1 2/4885
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 LMNA 3376/4885TYR 3830/4885DEGS1 2516/4885
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 LMNA 1994/4885TYR 4396/4885DEGS1 523/4885
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 LMNA 3376/4885TYR 3830/4885DEGS1 2516/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 LMNA 2013/4885TYR 4414/4885DEGS1 534/4885
US-12479834-B2 Phenol compound or salt thereof REN, MLX, MYB LMNA 1482/4885TYR 40/4885DEGS1 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.